[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Haaglanden Medical Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,75,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100504719","study-on-prognosis-of-acutely-ruptured-intracranial-aneurysms-100504719",false,"NCT05851989","Study on Prognosis of Acutely Ruptured Intracranial Aneurysms","SPARTA","Inclusion Criteria:\n\n* Confirmed diagnosis of subarachnoid haemorrhage on CT-scan or lumbar puncture (in the presence of a negative CT-scan)\n* Intracranial aneurysm proven within 6 months to be the cause of subarachnoid haemorrhage\n* Age 18 years or over at presentation.\n* Written informed consent\n\nExclusion Criteria:\n\n* Subarachnoid haemorrhage deemed most likely of 'perimesencephalic' origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)\n* Subarachnoid haemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging)\n* Diagnosis of intracerebral arteriovenous malformations or dural arteriovenous fistula.\n* No diagnosis of intracranial aneurysm at 6 months after onset of symptoms.\n* Not mastering the Dutch language","ALL","18 Years",{"count":19,"type":20},880,"ESTIMATED","OBSERVATIONAL","The SPARTA study is a prospective multicenter observational trial in the Netherlands with the aim of identifying the best clinical care in patients with aneurysmal subarachnoidal haemorrhage. Differences in outcome between surgical treatment and endovascular treatment will be explored.\n\nFurthermore, cost effectiveness and radiological prognostic factors will be examined.",[24,25,26,27,28],"Aneurysmal Subarachnoid Hemorrhage","Endovascular Procedures","Craniotomy","Patient Outcome Assessment","Treatment Outcome",[30,31,32,33,34,35,36],"Aneurysmal subarachnoid hemorrhage","Clipping","Neurosurgery","Coiling","Endovascular treatment","Outcome","Modified Rankin Scale","RECRUITING","2025-03-22",{"date":40,"type":41},"2025-03-25","ACTUAL",{"date":43,"type":41},"2021-07-14",{"date":45,"type":20},"2034-07-14",{"name":47,"class":48},"Haaglanden Medical Centre","OTHER",6,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100543739","phase-2-complement-inhibition-attacking-the-overshooting-inflammation-fter-subarachnoid-hemorrhage-ciaosah-100543739","NCT06359782","Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)","A Phase II Trial on the Safety and Efficacy of C1 Inhibitor for the Acute Management of Subarachnoid Hemorrhage","CIAO@SAH","Inclusion Criteria:\n\n* Confirmed diagnosis of aneurysmal subarachnoid hemorrhage on CT-scan;\n* Age ≥ 18 years on admission;\n* WFNS grade 1-5.\n\nExclusion Criteria:\n\n* Subarachnoid hemorrhage deemed most likely of 'peri mesencephalic' origin after consideration of history, clinical examination and radiological findings (including angiographic imaging); (not originated from an aneurysm and patients have by definition a favourable clinical outcome)\n* Subarachnoid hemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging); (does not occur spontaneous)\n* Participation in another clinical therapeutic study;\n* Patients with definite infaust prognosis on arrival and\u002For expected death within 24 hours of admission\n* Patients with a known hereditary complement deficiency (including hereditary angioedema);\n* Patients with a history of sensibility to blood products or C1-inhibitor;\n* Patients with a history of thrombosis (when known at time of inclusion);\n* Pregnant woman",{"count":59,"type":20},128,"INTERVENTIONAL",[62],"PHASE2","Aneurysmal subarachnoid hemorrhage (SAH) can lead to devastating outcomes for patients, like cognitive decline. This is caused by early brain injury (EBI) followed by delayed cerebral ischemia (DCI). Neuroinflammation, triggered by the complement system, has been investigated to be a key mediator in the pathophysiology of EBI and DCI. Inhibition of the complement system is therefore considered to be a potentially important new treatment for SAH.\n\nThis trial aims to study the safety and efficacy of C1-inhibitor Cinryze, an approved inhibitor of the complement system, compared to placebo in patients with SAH. By temporarily blocking the complement system we hypothesize limitation of delayed cerebral ischemia and a more favourable clinical outcome for SAH patients due to a decrease in the inflammatory response.",[65],"Subarachnoid Hemorrhage, Aneurysmal","2024-12-23",{"date":68,"type":41},"2024-12-27",{"date":70,"type":41},"2024-11-04",{"date":72,"type":20},"2027-03",{"name":47,"class":48},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":60,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":74},"100531787","towards-optimal-treatment-for-high-risk-prostate-cancer-100531787","NCT06204341","Towards Optimal Treatment for High Risk Prostate Cancer","Towards Optimal Treatment for High Risk Prostate Cancer; Stereotactic Pelvic Radiotherapy with Focal Boost to the Primary Tumour","HYPOPRIME","Inclusion Criteria:\n\n* Men (aged ≥18 years of age) diagnosed within 6 months before inclusion with high risk prostate cancer:\n\n  * T3 based on digital rectal examination AND\u002FOR\n  * Grade \\>= 4 AND\u002FOR\n  * PSA \\>=20 ug\u002FL\n* Indication for elective lymph node irradiation (based on current clinical guidelines) OR N1 on imaging (with a maximum of 4 suspect lymph nodes)\n\nExclusion Criteria:\n\n* Prior pelvic radiotherapy\n* TransUrethral Resection of the Prostate (TURP) \\\u003C 3 months ago\n* Prostatectomy or other primary treatment for prostate cancer (e.g. HIFU, cryotherapy, etc)\n* contraindications to MRI\n* no visible lesion on MRI in prostate for boost\n* no PSMA-PET scan\n* inflammatory bowel disease\n* metastatic disease (M1)\n* PSA \\>50\n* unsuitable for SBRT or WPRT\n* medical history of cancer other than basal cell carcinoma of the skin","MALE",{"count":85,"type":20},207,[87],"NA","The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.\n\n* patients will be irradiated on the prostate and (elective) lymph nodes more concentrated but with fewer hospital visits (hypofractionation)\n* the tumor will get a higher dose\n* androgen deprivation therapy will be reduced as much al possible preventing side effects\n\nResearchers will compare oncological outcome and toxicity.",[90],"High Risk Prostate Carcinoma",[92,93,94,95],"hypo fractionation","elective lymph node irradiation","focal boost","androgen deprivation therapy reduction","2024-09-10",{"date":98,"type":41},"2024-09-19",{"date":100,"type":41},"2024-01-02",{"date":102,"type":20},"2032-12-18",{"name":47,"class":48},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":60,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":125,"locationsCount":74},"100465872","improving-therapeutic-ratio-with-hypo-fractionated-stereotactic-radiotherapy-for-brain-metastases-100465872","NCT05346367","Improving Therapeutic Ratio With Hypo Fractionated Stereotactic Radiotherapy for Brain Metastases","SAFESTEREO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* At least one brain metastasis of large cell cancer suitable for SRT\n* Karnofsky Performance Status ≥ 70\n* Ability to provide written informed consent\n* New brain metastases during follow-up after surgery allowed (when outside of resection cavity area)\n* New brain metastases during follow-up after previous SRT allowed (when outside of previous irradiation field)\n\nExclusion Criteria:\n\n* Contra-indication for MRI scan\n* Primary tumor of small cell lung cancer, germinoma or lymphoma\n* Prior whole brain radiotherapy or SRT on the current target brain metastases (in field re-irradiation)\n* Presence of leptomeningeal metastases\n* Previous inclusion in the SAFESTEREO study",{"count":112,"type":20},130,[87],"Randomized phase II trial. The study aims to investigate a different and potentially safer radio therapeutic treatment method for brain metastases. The current standard of stereotactic radiotherapy (SRT) in one or three fractions is compared to fractionated stereotactic radiotherapy (fSRT) in five fractions.",[116],"Brain Metastases",[118],"fractionated stereotactic radiotherapy","2024-03-06",{"date":121,"type":41},"2024-03-12",{"date":123,"type":41},"2022-07-18",{"date":72,"type":20},{"name":47,"class":48},""]